Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05256745 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

RAGE Inhibition to Decrease Cardiotoxicity in Women With Early Breast Cancer

Study acronym: RAGE
StatusRecruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary and study completion dates: Oct 2025 to Dec 2026v13
  2. Primary completion date: Mar 2025 to Oct 2025 Completion date: Apr 2025 to Oct 2025 · Site contacts updated at 1 of 3 sitesv12 Show 2 more changesShow less
    • Completion date: Apr 2025 to Oct 2025
    • Site contacts updated at 1 of 3 sites
  3. Primary completion date: Nov 2024 to Mar 2025 Completion date: Nov 2024 to Apr 2025v11 Show 1 more changeShow less
    • Completion date: Nov 2024 to Apr 2025
  4. Study title shortened, about 1 wordv10 See this version in full on ClinicalTrials.gov ↗
  5. Site contacts updated at 1 of 3 sitesv9
Show 7 earlier versionsHide 7 earlier versions
  1. Site details revised at 1 of 3 sitesv8
  2. Study sites: 2 to 3 Start date changed from estimate of May 2023 to Jun 6, 2023v7 Show 1 more changeShow less
    • Start date changed from estimate of May 2023 to Jun 6, 2023
  3. Start date: Feb 2023 to May 2023 Study sites: 1 to 2v6 Show 1 more changeShow less
    • Study sites: 1 to 2
  4. Re-verified, no change to tracked fieldsv5
  5. Trial status: Not Yet Recruiting to Recruiting Primary and study completion dates: Nov 2023 to Nov 2024 · Start date: Nov 2022 to Feb 2023 · Eligibility criteria expanded, about 107 words · 2 morev4 Show 5 more changesShow less
    • Primary and study completion dates: Nov 2023 to Nov 2024
    • Start date: Nov 2022 to Feb 2023
    • Eligibility criteria expanded, about 107 words
    • Site details revised
    • Study title shortened, about 3 words

    See this version in full on ClinicalTrials.gov ↗

  6. Start date: Aug 2022 to Nov 2022v3
  7. Start date: May 2022 to Aug 2022 Primary endpoints: 3 to 4 · Secondary endpoints: details revised at 1 of 6 entriesv2 Show 2 more changesShow less
    • Primary endpoints: 3 to 4
    • Secondary endpoints: details revised at 1 of 6 entries

    See this version in full on ClinicalTrials.gov ↗

  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a pilot study to evaluate the effects of azeliragon to decrease cardiac toxicity from chemotherapy and the safety of azelirgaon when given with chemotherapy. The Investigators hypothesize that there will be no significant interaction with Azeliragon and chemotherapy and that targeting the RAGE pathway will decrease anthracycline related cardiotoxicity and chemotherapy related cognitive decline.
Trial Details
NCT Number NCT05256745
Lead Sponsor Georgetown University
Conditions Cancer Related Cognitive Decline, Non-metastatic Breast Cancer
Enrollment 48 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov